





CONTAINS CONFIDENTIAL PATIENT INFORMATION Belbuca (buprenorphine)

Prior Authorization of Benefits (PAB) Form
Complete form in its entirety and fax to:
Prior Authorization of Benefits Center at 1-844-512-9004
Provider Help Desk 1-800-454-3730

1. PATIENT INFORMATION		2. PHYSICIAN INFORM	2. PHYSICIAN INFORMATION	
Patient Name:		Prescribing Physician:		
Patient ID #:		Physician Address:	Physician Address:	
Patient DOB:		Physician Phone#: _		
Date of Rx:		Physician Fax #:	Physician Fax #:	
Patient Phone #:		Physician Specialty: _	Physician Specialty:	
Patient Email Address:			Physician DEA:	
		Physician NPI#:		
		Physician Email Address:	:	
a MEDICATION	4 0705110711			
3. MEDICATION	4. STRENGTH	5. DIRECTIONS	6. QUANTITY PER 30 DAYS	
Belbuca (buprenorphine	e)	-	Specify:	
7. DIAGNOSIS:		'	,	
8. APPROVAL CRITEI	RIA: CHECK ALL BOXES	THAT APPLY		
	lled out are considered not applic	able to your patient & MAY AFFE	ECT THE OUTCOME of this request.	
	Patient has had previous trials and therapy failures at a therapeutic dose with two long acting opioids (long acting narcotics: Methadone conc, methadone soln, methadone tab 5mg, 10mg, methadone			
			one tab 5mg, 10mg, methadone Con 10mg/ml, Kadian, morphine	
	ilfate tab ER, morphine sulfate, N		Con ronig/ini, Kadian, morphine	
	ocumented* evidence is provided	•	be medically contraindicated	
	Patient has had a previous trial and therapy failure with a short acting narcotic for breakthrough pain			
	hort acting narcotics include: cod			
			oxycodone, Roxicodone, Opana,	
	symorphone, Nucynta, Butrans, bubsolv, pentazocine w/ naloxone,			
	ercodan, oxycodone-ibuprofen, a			
	italbital-acetaminophen-caffeine			
	deine, Fiorinol/Codeine #3, Syna		acetaminophen, Norco, Xodol,	
1	/drocodone/ibuprofen, Ibudone,		II Parll Parl I	
	Documented* evidence is provided that use of these agents would be medically contraindicated			
	Patient has had a trial and therapy failure with fentanyl patch at maximum tolerated dose			
□ Yes □ No Documented* evidence is provided that use of this agent would be medically contraindicated *Documentation may include, but is not limited to, chart notes, prescription claims records, prescription receipts, and				
*Documentation may in laboratory data.	iciude, but is not limited to, chart	notes, prescription claims recor	as, prescription receipts, and	

PAGE 1 OF 2 CONTINUED ON PAGE 2







CONTAINS CONFIDENTIAL PATIENT INFORMATION Belbuca (buprenorphine)

Prior Authorization of Benefits (PAB) Form
Complete form in its entirety and fax to:
Prior Authorization of Benefits Center at 1-844-512-9004
Provider Help Desk 1-800-454-3730

Patient Name:	Patient ID#:			
9. PHYSICIAN SIGNATURE				
Prescriber or Authorized Signature	Date			
Prior Authorization of Benefits is not the practice of medicine or the substitute for the independ	= ****			

Prior Authorization of Benefits is not the practice of medicine or the substitute for the independent medical judgment of a treating physician. Only a treating physician can determine what medications are appropriate for a patient. Please refer to the applicable plan for the detailed information regarding benefits, conditions, limitations, and exclusions. The submitting provider certifies that the information provided is true, accurate, and complete and the requested services are medically indicated and necessary to the health of the patient.

Note: Payment is subject to member eligibility. Authorization does not guarantee payment.

The document(s) accompanying this transmission may contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation.

If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately and arrange for the return or destruction of these documents.

IAPEC-1177-18 PAGE 2 OF 2 October 2018